Lead Sponsor

Sanofi

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age\>40 years
•History of typical intermittent claudication lasting for at least 3 months, showing no improvement and consistent with treadmill test findings
•Objective evidence of Peripheral Arterial Occlusive Disease. After 10 minutes of rest, either by Ankle brachial index measure (ABI) \<0.8 or Systolic ankle pressure (AP) \< 50 mmHg or Systolic toe pressure \<50 mmHg
•Patent femoral inflow above the level of injections recently (\<2 weeks) documented either with Doppler ultrasonography or Magnetic Resonance Angiography or Angiography

•Evidence of other causes for leg pain other than intermittent claudication.
•Illnesses limiting subject exercise capacity (angina pectoris, heart failure, respiratory disease, orthopaedic disease, neurological disorders…)
•Pain at rest
•Buerger's disease
•Positive serology for HIV 1 or 2, positive serology hepatitis B or C.
•Subjects with serum creatinine \> 2 mg/dl (176 µmol/l) and subjects on dialysis.
•Active proliferative retinopathy defined by the presence of new vessel formation and scarring.
•Subjects who had a stroke or neurologic deficit presumed to be due to stroke within 3 months prior to the first administration of study treatment
•Previous treatment with any angiogenic growth factor
•Pregnant or breast feeding women or who disagree to practice a medically accepted method of birth control. Men and women who do not agree to use condoms as the only accepted protection barrier, for the entire study period
•Serious concomitant medical conditions not adequately controlled.
•Current alcohol or drug abuse
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related studies

NCT06832631 · Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease

NCT06204237 · Peripheral Arterial Occlusive Disease, Critical Limb Ischemia

NCT05961943 · Peripheral Arterial Disease, Sedentary Behavior, and more

NCT06056193 · Peripheral Arterial Occlusive Disease, Bypass Complication, and more

NCT06980064 · Coronary Stenosis, Cerebral Arterial Diseases, and more

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication